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Background and aims: No prospective study has investigated whether individuals with respiratory im-
pairments, including chronic obstructive pulmonary disease (COPD) and restrictive lung disease (RLD),
are at increased risk of abdominal aortic aneurysm (AAA). We aimed to prospectively investigate
whether those respiratory impairments are associated with increased AAA risk.
Methods: In 1987e1989, the Atherosclerosis Risk in Communities (ARIC) study followed 14,269 partic-
ipants aged 45e64 years, without a history of AAA surgery, through 2011. Participants were classified
into four groups, “COPD” [forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <lower limit
of normal (LLN)], “RLD” (FEV1/FVC  LLN and FVC < LLN), “respiratory symptoms with normal
spirometry” (without RLD or COPD), and “normal” (without respiratory symptoms, RLD or COPD,
reference group).
Results: During the 284,969 person-years of follow-up, 534 incident AAA events were documented. In an
age, sex, and race-adjusted proportional hazards model, individuals with respiratory impairments had a
significantly higher risk of AAA than the normal reference group. After adjustment for AAA risk factors,
including smoking status and pack-years of smoking, AAA risk was no longer significant in the respi-
ratory symptoms with normal spirometry group [HR (95% CI), 1.25 (0.98e1.60)], but was still increased in
the other two groups [RLD: 1.45 (1.04e2.02) and COPD: 1.66 (1.34e2.05)]. Moreover, continuous mea-
sures of FEV1/FVC, FEV1 and FVC were associated inversely with risk of AAA.
Conclusions: In the prospective population-based cohort study, obstructive and restrictive spirometric
patterns were associated with increased risk of AAA independent of smoking, suggesting that COPD and
RLD may increase the risk of AAA.
© 2017 Elsevier B.V. All rights reserved.1. Introduction
Abdominal aortic aneurysm (AAA) is a common disease in
Western populations, especially in elderly people [1]. Once rupture
occurs, mortality rates can be as high as 65e85% [2]. So far, there is
no established treatment for AAA other than surgery. Since AAA is
usually asymptomatic and AAA growth is discontinuous, with pe-
riods of growth alternating with periods of stability, it is oftend Community Health, School
2nd Street, Minneapolis, MNdifficult to estimate the prognosis of AAA or offer interventions [3].
Thus, it is important to identify populations with high risk of AAA.
Some research has suggested that chronic obstructive pulmo-
nary disease (COPD) is associated with increased risks of AAA and
its rupture [4e9]. A previous clinical cross-sectional study showed
that this associationwas independent of smoking, and mediated by
inflammation and hemostasis [9]. A previous population-based
study showed that circulating inflammatory and hemostatic
markers are prospectively associated with AAA events [10], and
thus, inflammatory lung diseases, like COPD or restrictive lung
diseases (RLD), as sources of circulating inflammatory products,
may contribute to AAA. However, to the best of our knowledge, no
prospective epidemiological study has examined the association
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Therefore, the objective of this study was to prospectively
investigate whether respiratory impairments including COPD and
RLD, assessed by spirometry and respiratory symptoms, are asso-
ciated with increased incidence of AAA in a population-based study
in the U.S., the Atherosclerosis Risk in Communities (ARIC) study.
2. Materials and methods
2.1. Study population
The ARIC study is an ongoing population-based prospective
investigation aimed to identify risk factors for cardiovascular dis-
eases [11]. In 1987e1989, the ARIC study recruited and examined
15,792 mostly white or African American men and women aged
45e64 years, within 4 U.S. communities (Washington County, MD;
Forsyth County, NC; Jackson, MS (African Americans only); and
suburbs of Minneapolis, MN).
The ARIC study was approved by the institutional review boards
of the collaborating universities, and written informed consent was
obtained from all participants.
2.2. Main exposure: lung function and respiratory symptoms
ARIC conducted spirometry at visit 1 baseline using a water-
sealed Collins Survey II volume displacement spirometer (Collins
Survey II; Collins Medical; Braintree, MA) and Pulmo-Screen II
software (Pulmo-Screen; PDS Healthcare Products; Louisville, CO)
[12]. Using the Hankinson 1999 equations, forced expiratory vol-
ume in 1 s (FEV1) as a percentage of predicted value (FEV1% pre-
dicted), forced vital capacity (FVC) as a percentage of predicted
value (FVC % predicted), and the lower limit of normal (LLN) were
calculated [13]. ARIC did not evaluate bronchodilator (beta-agonist)
response at visit 1.
Respiratory symptoms were assessed using a standardized self-
administered questionnaire [14]. Participants were considered as
having respiratory symptoms when they answered positively to
any of the following questions [15]: “Do you usually have a
cough?”; “Do you usually bring up phlegm from your chest?”;
“Does your chest ever sound wheezy or whistling apart from
colds?”; “Do you have towalk slower than people of your age on the
level because of breathlessness?”; and “Are you too breathless to
leave the house or breathless on dressing or undressing?”.
Participants were classified into 4 categories as follows:
“Normal”was defined as thosewith FEV1/FVC LLN, FVC LLN and
no respiratory symptoms, “respiratory symptoms with normal
spirometry” as those with respiratory symptoms but FEV1/
FVC  LLN and FVC  LLN, “RLD pattern” as FEV1/FVC  LLN and
FVC < LLN, and “COPD pattern” as FEV1/FVC < LLN [15].
2.3. Potential confounding factors
Potential confounding factors included age, sex, race (white or
African American), height (cm), smoking status (current, former or
never), pack-years of smoking, hypertension (systolic blood pres-
sure 140 mmHg, diastolic blood pressure 90 mmHg or hyper-
tension medication use) [16], diabetes mellitus (a fasting blood
glucose 126 mg/dl, non-fasting blood glucose 200 mg/dl, a self-
reported physician diagnosis of diabetes, or use of antidiabetic
medication in the past 2 weeks) [17], HDL cholesterol (mmol/L),
LDL cholesterol (mmol/L), and history of peripheral artery disease.
Since our previous study showed that obesity was not associated
with AAA risk [18], weight and body mass index were not consid-
ered as potential confounders, although they were presented in
baseline characteristics.2.4. Ascertainment of abdominal aortic aneurysm
Incident clinical AAAs were identified by the following several
strategies [10,18]: ARIC interviewers asked with annual telephone
calls about any interim hospitalizations and identified deaths. ARIC
also surveyed local hospitals to identify additional hospitalizations
or deaths. In addition, ARIC linked participant identifiers with fee-
for-service Medicare data from the Centers for Medicare and
Medicaid Services for 1991e2011, to find additional hospital or
outpatient events for those over 65 years. Incident clinical AAAs
were defined as those with a hospital discharge diagnosis from any
source, or two Medicare outpatient claims that occurred at least
one week apart, with ICD-9-CM codes of 441.3 or 441.4, or pro-
cedure codes of 38.44 or 39.71, or death codes of ICD-9441.3 or
441.4 or ICD-10 code I71.3 or I71.4. AAAs based on procedure codes
were required to be verified by diagnosis codes. Some of these
clinical diagnoses would include asymptomatic AAAs medically
documented. Thoracic, thoracoabdominal, or unspecified aortic
aneurysms were treated as non-events.
2.5. Statistical analysis
SAS version 9.4 software (SAS Institute Inc., Cary, NC) was used
for statistical analyses. All statistical tests were two-tailed and p
values < 0.05 were considered as significant.
From a total of 15,972 participants, the following participants
were excluded; participants who reported prior AAA surgery
(n ¼ 11) at baseline, had uncertain AAA status during follow-up
(n ¼ 30), non-white participants in Washington County or Min-
neapolis or non-white/black participants in Forsyth County
(n ¼ 48) in order to allow multivariable adjustment for race and
study site [19], and participants whose data on main exposures
(n ¼ 197) or any covariates (n ¼ 1237) were missing. Finally, 14,269
participants were included in the present analyses.
Person-years of follow-up were calculated from baseline to the
first endpoint: AAA, death (non-AAA related death was censored at
the time of death), loss to follow-up, or administrative censoring at
December 31, 2011. Hazard ratios (HRs) and their 95% confidence
intervals (CIs) of clinical AAA were calculated using Cox propor-
tional hazard models. The proportional hazards assumption in the
Cox regression was tested using risk factor-by-time interactions
and was not violated. Since we found no statistical interactions
between sex or race and respiratory categories in relation to AAA
risk (p for interaction >0.05), we pooled the analysis across sex and
race. We also found no interaction about age. We constructed cubic
spline graphs with 3 knots at 25, 50 and 75 percentiles in order to
examine dose-response relationships between continuous mea-
sures of FEV1% predicted, FVC % predicted or FEV1/FVC and AAA
risk.
Several sensitivity analyses were performed: (i) the associations
between respiratory impairments and AAA risk were examined
after stratifying participants by smoking status, (ii) multiplicative
interactions were tested between respiratory impairments and
smoking status or pack-years in the overall AAA multivariable
model, models were rerun after (iii) excluding AAA cases identified
by Medicare data, (iv) excluding early AAA events (within 10 years
of baseline) and/or participants who were 60e64 years old to
reduce the influence of unidentified AAA at baseline, and (v)
excluding participants with diabetes at baseline.
3. Results
3.1. Baseline characteristics according to lung function categories
Characteristics of this study are shown in Table 1. Individuals
Table 1
Baseline characteristics of participants according to respiratory impairments, ARIC, 1987e1989 (n ¼ 14,269).
Normal Respiratory symptoms with normal spirometry Restrictive lung disease pattern COPD pattern
Participants, n 8653 2280 841 2495
AAA risk factors
Age, y 53.8 ± 5.7 54.2 ± 5.7 54.6 ± 5.6 55.0 ± 5.8
Female, % 56.3 57.8 52.1 50.3
African American, % 26.3 27.5 19.4 21.5
Height, cm 168.4 ± 9.3 167.6 ± 9.1 168.9 ± 9.3 169.7 ± 9.5
Diabetes mellitus, % 10.0 14.0 21.6 8.8
Current smoker, % 15.3 35.3 35.1 49.2
Pack-years of smoking 10.8 ± 17.2 17.8 ± 22.7 20.7 ± 23.2 30.2 ± 26.4
Hypertension, % 32.3 38.2 45.5 30.9
LDL cholesterol, mmol/L 3.6 ± 1.0 3.6 ± 1.0 3.6 ± 1.1 3.5 ± 4.8
HDL cholesterol, mmol/L 1.4 ± 0.4 1.3 ± 0.4 1.2 ± 0.4 1.4 ± 0.5
Peripheral artery disease, % 3.1 4.4 5.8 6.5
Obesity measures
Weight, kg 78.1 ± 16.1 80.3 ± 17.2 86.0 ± 19.6 75.0 ± 16.1
Body mass index, kg/m2 27.6 ± 5.0 28.7 ± 5.8 30.2 ± 6.5 26.0 ± 4.8
Respiratory measures
FEV1% predicted 100.2 ± 12.1 96.6 ± 12.1 72.6 ± 8.1 74.9 ± 18.2
FVC % predicted 101.6 ± 11.7 98.9 ± 11.6 72.8 ± 7.2 94.0 ± 17.8
FEV1/FVC, % 77.2 ± 4.7 76.5 ± 4.8 78.0 ± 6.2 61.5 ± 7.7
Respiratory symptoms, % 0 100 37.9 46.7
ARIC, Atherosclerosis Risk in Communities study; AAA, abdominal aortic aneurysm; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LLN, lower limit of normal.
Using spirometry without bronchodilator. Normal was defined as FEV1/FVC  LLN and FVC  LLN, respiratory symptoms with normal spirometry as those with respiratory
symptoms but FEV1/FVC  LLN and FVC  LLN, restrictive lung disease pattern as FEV1/FVC  LLN and FVC < LLN, and COPD pattern as FEV1/FVC < LLN.
Values are mean ± standard deviation for continuous variables and % for categorical variables.
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tended to be older, current smokers, have more pack-years, and
have reported history of peripheral artery disease compared to
those in the normal group. Participants with RLD pattern were
likely to be heavier, while thosewith COPD pattern tended to have a
lower body weight.3.2. Associations of respiratory categories with abdominal aortic
aneurysm
During the 284,969 person-years of follow-up, over a median of
22.5 years, 534 incident, clinical AAA events were documented
(Table 2). The age-, sex-, and race-adjusted model (Model 1)
showed that individuals with respiratory symptoms and normal
spriometry, with the RLD pattern, or with the COPD pattern had
increased risk of AAA compared to normal participants. Further
adjustment for the other potential confounding factors (Model 2)
attenuated those associations, but individuals with the RLD [HR
(95% CI): 1.45 (1.04e2.02)] or COPD [1.66 (1.34e2.05)] pattern still
had a significantly elevated risk of AAA.Table 2
Hazard ratios and 95% confidence intervals for incident, clinical abdominal aortic aneury
Normal Respiratory symptoms with normal spir
No. at risk 8653 2280
Person-years 179,183 44,456
Cases 219 96
Model 1 1 1.86 (1.46e2.36)
Model 2 1 1.25 (0.98e1.60)
ARIC, Atherosclerosis Risk in Communities study; FEV1, forced expiratory volume in 1 s;
Using spirometry without bronchodilator. Normal was defined as FEV1/FVC  LLN and F
symptoms but FEV1/FVC  LLN and FVC  LLN, restrictive lung disease pattern as FEV1/F
Model 1: adjusted for age, sex, and race/ARIC field center.
Model 2: adjusted for Model 1 factorsþ height, smoking status, pack-years of smoking, hy
disease.3.3. Dose-response relations of continuous spirometry
measurements with abdominal aortic aneurysm
The continuous relations of FEV1/FVC, FEV1% predicted, and FVC
% predicted with AAA incidence were assessed using restricted
cubic splines to evaluate how the degree of lung restriction or
airway obstruction was associated with AAA risk (Fig. 1). Lower
levels of all three spriometry measurements were significantly
associated with increased risks of AAA (inverse dose-response
relations).
3.4. Sensitivity analyses
Among current smokers (Table 3), all three respiratory impair-
ments groups (respiratory symptoms and normal spirometry, RLD,
and COPD) had significantly higher risks of AAA than the normal
group. Similar trends were seen among former and never smokers
(Table 3), though the associations were not statistically significant.
FEV1/FVC was inversely associated with AAA risk in current and
former smokers, and was marginally associated in never smokers
(p ¼ 0.08) (Table 4). Inverse associations of FEV1 and FVC with AAA
were observed in only current smokers.
There were no significant interactions between smoking status
(Tables 3 and 4) or pack-years (data not shown) and the respiratorysm according to respiratory impairments, ARIC, 1987e2011 (n ¼ 14,269).




2.40 (1.74e3.32) 3.04 (2.49e3.71)
1.45 (1.04e2.02) 1.66 (1.34e2.05)
FVC, forced vital capacity; LLN, lower limit of normal.
VC  LLN, respiratory symptoms with normal spirometry as those with respiratory
VC  LLN and FVC < LLN, and COPD pattern as FEV1/FVC < LLN.
pertension, diabetes mellitus, LDL cholesterol, HLD cholesterol and peripheral artery
Fig. 1. Multivariably adjusted (Model 2) associations of FEV1 as a percentage of pre-
dicted value (FEV1% predicted), FVC as a percentage of predicted value (FVC % pre-
dicted), or FEV1/FVC with AAA.
Solid and dashed lines represent hazard ratios and 95% confidence interval, respec-
tively. The reference value was the median value of the fourth quartile (87.5th
percentile).
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Excluding AAA cases identified by Medicare data only (n ¼ 143,
27% of total cases), early AAA events, participants who were 60e64years old or those with diabetes at baseline produced results
similar to the main results (data not shown).
4. Discussion
In the prospective population-based ARIC cohort, participants
with baseline RLD or COPD patterns had increased risk of incident
AAA, independent of other AAA risk factors, including smoking. In
addition, lower FEV1% predicted and FEV1/FVC, indices of airway
obstruction, and FVC % predicted, an index of lung restriction, were
independently associated with elevated risk of AAA.
AAA is the result of multifactorial processes in the aorta,
including inflammation, genetic abnormalities, biomechanical wall
stress, apoptosis, and proteolytic degradation of connective tissue,
which result in alterations in the structural integrity of the extra-
cellular matrix, leading to AAA formation [20]. Inflammation is
considered to be a key component in AAA formation. Several
proinflammatory cytokines, including interleukin-6, interleukin-
1b, tumor necrosis factor-a, and interferon-g, have been identified
in AAA walls [21e23]. These cytokines activate lymphocytes and
macrophages, and promote matrix metalloproteinase production
[24,25]. These upregulated matrix metalloproteinases degrade the
matrix structural proteins elastin and collagen, leading to AAA.
COPD and RLD are inflammatory lung diseases, and they have been
associated with elevated markers of systemic inflammation and
hemostasis, such as interleukin-6, tumor necrosis factor-a and D-
dimer [9,26e30]. Previous studies, mostly cross-sectional, have
shown positive associations of plasma inflammatory markers, such
as C-reactive protein and interleukin-6 with AAA risk [31]. In-
flammatory factors also activate hemostasis, potentially contrib-
uting to intraluminal thrombi, which are also important
characteristics of AAA [9]. ARIC previously reported that D-dimer
was associated with an increased risk of AAA [10]. Thus, increased
systemic hemostatic (or thrombogenic) factors from respiratory
impairments may also contribute to AAA pathophysiology.
Airway obstruction was particularly strongly associated with
increased risk of AAA. Although airway obstruction as seen in COPD
affects primarily the right side of the heart (e.g., cor pulmonale in
severe COPD), a previous study showed that pulmonary hyperin-
flation is associated with greater left ventricular mass independent
of blood pressure and other traditional CVD risk factors among
COPD patients [32], suggesting that COPD may increase the after-
load of left ventricle, i.e. aortic pressure (aortic wall stress). In fact,
left ventricular hypertrophy has been reported to be associated
with a greater diameter of the abdominal aorta, as well as the
thoracic aorta [33,34]. This might be another potential mechanism
linking airway obstruction with AAA.
Associations between lung function and AAA were qualitatively
and statistically (as evidenced by no interaction) similar for current,
ever and never smokers, although most associations were not
statistically significant for the former and never smoking sub-
groups, because few AAAs occurred in them. Although this study
adjusted for pack-years of smoking, as well as smoking status in the
main analysis, the possibility of residual confounding by smoking
explaining our findings cannot be completely ruled out.
Compared to the normal group, individuals with respiratory
symptoms and normal spirometry, particularly among the current
smokers, also had an increased risk of AAA. Respiratory symptoms
with preserved lung function may have included borderline COPD
or RLD at baseline. In fact, a recent study showed that smokers with
respiratory symptoms, but who did not meet spirometric criteria
for COPD, had similar adverse health outcomes to those meeting
the spirometric definition of COPD [35]. In addition, respiratory
symptoms might have reflected underlying inflammatory condi-
tions such as chronic pneumonia. In any case, respiratory
Table 3
Hazard ratios and 95% confidence intervals for incident, clinical abdominal aortic aneurysm according to respiratory impairments, stratified by smoking status, ARIC,
1987e2011 (n ¼ 14,269).
Normal Respiratory symptoms with normal spirometry Restrictive lung disease pattern COPD pattern
Current smokers
No. at risk 1323 804 295 1228
Person-years 25,428 14,904 5279 20,077
Cases 63 60 27 121
Model 2 1 1.47 (1.03e2.11) 1.64 (1.04e2.59) 2.05 (1.50e2.81)
Former smokers
No. at risk 2952 578 252 761
Person-years 60,530 11,442 4410 14,274
Cases 106 25 14 47
Model 2 1 1.09 (0.70e1.69) 1.34 (0.76e2.36) 1.37 (0.96e1.95)
Never smokers
No. at risk 4378 898 294 506
Person-years 93,225 18,130 5721 10,649
Cases 50 11 3 7
Model 2 1 1.23 (0.64e2.37) 1.12 (0.35e3.60) 1.20 (0.54e2.66)
p for interaction 0.48
ARIC, Atherosclerosis Risk in Communities study; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LLN, lower limit of normal.
Using spirometry without bronchodilator. Normal was defined as FEV1/FVC  LLN and FVC  LLN, respiratory symptoms with normal spirometry as those with respiratory
symptoms but FEV1/FVC  LLN and FVC  LLN, restrictive lung disease pattern as FEV1/FVC  LLN and FVC < LLN, and COPD pattern as FEV1/FVC < LLN.
Model 2: adjusted for age, sex, race/ARIC field center, height, pack-years of smoking, hypertension, diabetes mellitus, LDL cholesterol, HLD cholesterol and peripheral artery
disease.
Table 4
Hazard ratios and 95% confidence intervals for incident, clinical abdominal aortic
aneurysm according to continuous spirometry measures, stratified by smoking
status, ARIC, 1987e2011 (n ¼ 14,269).
FEV1/FVCa FEV1% predicteda FVC % predicteda
Current smokers
No. at risk 3650 ) )
Person-years 65,687 ) )
Cases 271 ) )
Model 2 0.81 (0.73e0.90) 0.77 (0.69e0.87) 0.86 (0.76e0.97)
Former smokers
No. at risk 4534 ) )
Person-years 90,636 ) )
Cases 192 ) )
Model 2 0.88 (0.77e0.99) 0.89 (0.77e1.03) 0.98 (0.83e1.14)
Never smokers
No. at risk 6076 ) )
Person-years 127,725 ) )
Cases 71 ) )
Model 2 0.79 (0.60e1.03) 0.90 (0.68e1.19) 1.02 (0.79e1.32)
p for interaction 0.75 0.24 0.15
ARIC, Atherosclerosis Risk in Communities study; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; LLN, lower limit of normal.
Model 2: adjusted for age, sex, race/ARIC field center, height, pack-years of smoking,
hypertension, diabetes mellitus, LDL cholesterol, HLD cholesterol and peripheral
artery disease.
a Per 1-SD increment.
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among smokers.
Participants with COPD pattern were less likely to have diabetes
or hypertension than the normal group, which appears inconsistent
with previous reports [36,37]. Althoughwe have no clear reason for
this discrepancy, one possible reason might be that those with
COPD pattern were less likely to be obese.
Some limitations should be considered. Firstly, the present
study assessed lung function and respiratory symptoms only at
baseline, and thus, during the follow-up, some participants in the
normal group might have developed respiratory impairments. In
addition, “COPD pattern” was defined on the basis of spirometry
values without the administration of bronchodilator. Although we
assumed that the COPD pattern defined in the present study was
mainly COPD as in other epidemiological studies [38,39], someparticipants without lung disease might have been included in the
COPD pattern. However, those misclassifications would tend to bias
the results toward the null, and thus do not explain the observed
associations. Secondly, the assessment of clinical AAA was limited
to hospital and death ICD codes [10,19]. Although there is no direct
evidence of the validity of ICD codes for AAA, the AAA codes seem
quite specific, but also insensitive for capturing AAA events. Thus,
the approach used in this study might have led to an underesti-
mation of AAA events. Thirdly, the few participants were excluded
who had AAA repair before baseline without baseline ultrasound
screening. Thus, some participants with prevalent AAA might have
been included in the present study. However, given the fact that
ARIC participants were 45e65 years old at baseline, and sensitivity
analyses produced results similar to themain results, the number of
prevalent AAAs mistakenly included should have been low. Finally,
we excluded a relatively large number of participants from the
analyses. Although we found excluded participants had character-
istics similar to analyzed participants, we cannot deny the possi-
bility that this might have led to bias.
In conclusion, in this prospective biracial cohort, obstructive and
restrictive spirometric patterns were associated with increased risk
of AAA independent of smoking, suggesting that COPD and RLD
may increase the risk of AAA.Conflict of interest
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